SRR8942957
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.490
- TNFA_SIGNALING_VIA_NFKB+0.440
- INTERFERON_GAMMA_RESPONSE+0.420
- DNA_REPAIR+0.350
- IL6_JAK_STAT3_SIGNALING+0.350
- E2F_TARGETS+0.330
- P53_PATHWAY+0.330
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.300
- INFLAMMATORY_RESPONSE+0.300
- COMPLEMENT+0.260
Top 10 suppressed
- MYC_TARGETS_V2-0.310
- MYC_TARGETS_V1-0.240
- APICAL_SURFACE-0.220
- FATTY_ACID_METABOLISM-0.200
- HEDGEHOG_SIGNALING-0.180
- WNT_BETA_CATENIN_SIGNALING-0.160
- ADIPOGENESIS-0.140
- ANDROGEN_RESPONSE-0.140
- KRAS_SIGNALING_DN-0.130
- OXIDATIVE_PHOSPHORYLATION-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-XF-A8HD-01A-11R-A36F-07 | — | — | 0.843 |
| 2 | TCGA-DK-A2I4-01A-11R-A21D-07 | — | — | 0.793 |
| 3 | SRR1516052 | — | — | 0.791 |
| 4 | MNG745 | — | — | 0.790 |
| 5 | MNG751 | — | — | 0.778 |
| 6 | C3L-00904 | — | cohortSQ1 | 0.770 |
| 7 | 25400212-48de-48a9-96d3-2fc2ee23fd41 | — | — | 0.761 |
| 8 | SRR35579823 | — | D | 0.760 |
| 9 | SRR1445895 | GTEX | — | 0.758 |
| 10 | SRR10900560 | — | — | 0.757 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.490 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.440 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.420 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.350 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.330 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.300 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.300 | Idelalisib | — uncovered |
| COMPLEMENT | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.250 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.220 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.210 | Idelalisib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.170 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.170 | Idelalisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |